Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Invictus MD Strategies Corp IVITF

Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.


GREY:IVITF - Post by User

Post by GoodLuck14on Nov 25, 2019 9:48am
191 Views
Post# 30388831

GENE CLOSES TERMINATION OF AUTHENTIC BRANDS GROUP LICENSE

GENE CLOSES TERMINATION OF AUTHENTIC BRANDS GROUP LICENSE
INVICTUS CLOSES TERMINATION OF AUTHENTIC BRANDS GROUP LICENSE AGREEMENT

Vancouver, B.C., Nov. 25, 2019 (GLOBE NEWSWIRE) -- INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS2) the Company is pleased to announce the completion, effective September 30, 2019, of the previously announced termination of its license agreement with ABG-HMX, LLC pursuant to an omnibus settlement and termination agreement (the “Agreement”).  The Company sought and received regulatory approval from the TSX Venture Exchange to complete the termination.

Further to the description of the terms and conditions of the Agreement in the Company's news release dated October 23, 2019, in accordance with TSXV requirements, the Agreement was amended to institute a minimum per share issue price of $0.12 as opposed to $0.11625 for any share consideration issued in connection with the Company’s payment obligations under the Agreement.  For more information, please visit www.invictus-md.com.

Marc Ripa

Interim Chief Executive Officer

Investor Relations 1-844-800-6086


<< Previous
Bullboard Posts
Next >>